Cerity Partners LLC Acquires New Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Cerity Partners LLC acquired a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 135,652 shares of the company’s stock, valued at approximately $665,000. Cerity Partners LLC owned approximately 0.09% of Adaptive Biotechnologies as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of Adaptive Biotechnologies by 46.6% in the third quarter. SG Americas Securities LLC now owns 58,720 shares of the company’s stock worth $320,000 after purchasing an additional 18,658 shares during the last quarter. ARK Investment Management LLC grew its stake in shares of Adaptive Biotechnologies by 10.1% in the third quarter. ARK Investment Management LLC now owns 11,509,308 shares of the company’s stock worth $62,726,000 after acquiring an additional 1,055,556 shares during the period. DDD Partners LLC purchased a new position in shares of Adaptive Biotechnologies during the third quarter valued at approximately $4,271,000. Commonwealth Equity Services LLC lifted its position in Adaptive Biotechnologies by 6.8% during the third quarter. Commonwealth Equity Services LLC now owns 55,264 shares of the company’s stock valued at $301,000 after purchasing an additional 3,498 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Adaptive Biotechnologies by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 375,908 shares of the company’s stock worth $2,049,000 after purchasing an additional 2,325 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, CFO Tycho Peterson sold 15,456 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.44, for a total value of $53,168.64. Following the completion of the transaction, the chief financial officer now owns 531,553 shares of the company’s stock, valued at $1,828,542.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Adaptive Biotechnologies news, President Julie Rubinstein sold 39,070 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $3.47, for a total value of $135,572.90. Following the sale, the president now directly owns 472,754 shares in the company, valued at approximately $1,640,456.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Tycho Peterson sold 15,456 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $3.44, for a total transaction of $53,168.64. Following the completion of the sale, the chief financial officer now owns 531,553 shares in the company, valued at approximately $1,828,542.32. The disclosure for this sale can be found here. Insiders have sold a total of 124,307 shares of company stock valued at $428,090 over the last ninety days. 5.20% of the stock is currently owned by company insiders.

Adaptive Biotechnologies Stock Up 2.8 %

Shares of ADPT opened at $2.58 on Wednesday. Adaptive Biotechnologies Co. has a 52 week low of $2.28 and a 52 week high of $9.08. The stock has a market cap of $374.33 million, a price-to-earnings ratio of -1.71 and a beta of 1.25. The business has a 50-day simple moving average of $3.33 and a two-hundred day simple moving average of $4.03.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. Adaptive Biotechnologies had a negative net margin of 132.29% and a negative return on equity of 53.65%. The firm had revenue of $45.78 million for the quarter, compared to the consensus estimate of $50.15 million. On average, equities analysts anticipate that Adaptive Biotechnologies Co. will post -1.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ADPT has been the topic of several research analyst reports. BTIG Research lowered their price target on Adaptive Biotechnologies from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, April 4th. JPMorgan Chase & Co. dropped their target price on Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating on the stock in a research report on Thursday, February 15th. Finally, The Goldman Sachs Group dropped their price objective on shares of Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, February 16th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $6.80.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.